GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Repurchase of Stock

Armata Pharmaceuticals (FRA:TG1N) Repurchase of Stock : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals Repurchase of Stock?

Armata Pharmaceuticals's Repurchase of Stock for the three months ended in Mar. 2024 was €0.00 Mil.

Armata Pharmaceuticals's Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Armata Pharmaceuticals Repurchase of Stock Historical Data

The historical data trend for Armata Pharmaceuticals's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Repurchase of Stock Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Armata Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Armata Pharmaceuticals Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Armata Pharmaceuticals Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Armata Pharmaceuticals (FRA:TG1N) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Repurchase of Stock
Comparable Companies
ORMP RLMD VANI MIST LPTX PLX CLSD ATHA DTIL CGTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ARMP:USA TG1M:Germany
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Website
https://www.armatapharma.com
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals (FRA:TG1N) Headlines

No Headlines